|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer显示文摘Irinotecan hydrochloride is a camptothecin derivative that exerts antitumor activity against a variety of tumors. SN-38 produced in the body by carboxylesterase is the active metabolite of irinotecan. After irinotecan was introduced for the treatment of metastatic colorectal cancer(CRC) at the end of the last century,survival has improved dramatically. Irinotecan is now combined with 5-fluorouracil,oxaliplatin and several molecularly-targeted anticancer drugs,resulting in the extension of overall survival to longer than 30 mo. Severe,occasionally life-threatening toxicity occurs sporadically,even in patients in relatively good condition who have a low risk of chemotherapyinduced toxicity,often causing the failure of irinotecanbased chemotherapy. Clinical pharmacological studies have revealed that such severe toxicity is related to exposure to SN-38 and genetic polymorphisms in UDPglucuronosyltransferase 1A1 gene. The large interand intra-patient variability in systemic exposure to SN-38 is determined not only by genetic factors but also by physiological and environmental factors. This review first summarizes the roles of irinotecan in chemotherapy for metastatic CRC and then discusses the optimal dosing of irinotecan based on the aforementioned factors affecting systemic exposure to SN-38,with the ultimate goal of achieving personalized irinotecan-based chemotherapy. | Ken-ichi Fujita Yutaro Kubota Hiroo Ishida Yasutsuna Sasaki | 2015 | World Journal of Gastroenterology2015，21，43： | 22 |
| 2 | Phase II trial of nanoparticle albumin‐bound paclitaxel as second‐line chemotherapy for unresectable or recurrent gastric cancer显示文摘 | Yasutsuna Sasaki Tomohiro Nishina Hirofumi Yasui Masahiro Goto Kei Muro Akihito Tsuji Wasaburo Koizumi Yasushi Toh Takuo Hara Yoshinori Miyata | 2014 | Cancer Sci2014，，7： | 2 |
| 3 | Direct Inhibition and Down-regulation by Uremic Plasma Components of Hepatic Uptake Transporter for SN-38, an Active Metabolite of Irinotecan, in Humans显示文摘 | Ken-ichi Fujita Tomoko Sugiura Hidenori Okumura Saki Umeda Noritaka Nakamichi Yusuke Watanabe Hiromichi Suzuki Yu Sunakawa Ken Shimada Kaori Kawara Yasutsuna Sasaki Yukio Kato | 2014 | Pharmaceutical Research2014，，1： | 1 |
| 4 | Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer显示文摘 | Ken-ichi Fujita Yuichi Ando Fumio Nagashima Wataru Yamamoto Hisashi Eodo Kazuhiro Araki Keiji Kodama Toshimichi Miya Masaru Narabayashi Yasutsuna Sasaki | 2007 | Cancer Chemotherapy and Pharmacology2007，，4： | 1 |
| 5 | Factors Affecting the Pharmacokinetics of CPT-11: The Body Mass Index, Age and Sex are Independent Predictors of Pharmacokinetic Parameters of CPT-11显示文摘 | Toshimichi Miya Tomoyuki Goya Hirofumi Fujii Tomoko Ohtsu Kuniaki Itoh Tadahiko Igarashi Hironobu Minami Yasutsuna Sasaki | 2001 | Investigational New Drugs2001，，1： | 1 |
| 6 | Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms显示文摘 | Taroh Satoh Takashi Ura Yasuhide Yamada Kentaro Yamazaki Toshimasa Tsujinaka Masaki Munakata Tomohiro Nishina Shu Okamura Taito Esaki Yasutsuna Sasaki Wasaburo Koizumi Yoshihiro Kakeji Naoki Ishizuka Ichinosuke Hyodo Yuh Sakata | 2011 | Cancer Science2011，，10： | 1 |
| 7 | Re-treatment of relapsed indolent B-Cell lymphoma with rituximab显示文摘 | Tadahiko Igarashi Tomoko Ohtsu Hirofumi Fujii Yasutsuna Sasaki Yasuo Morishima Michinori Ogura Yoshitoyo Kagami Tomohiro Kinoshita Masaharu Kasai Yoshio Kiyama Yukio Kobayashi Kensei Tobinai | 2001 | International Journal of Hematology2001，，2： | 1 |
| 8 | Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR)显示文摘 | Hiromichi Ebi Yasushi Sigeoka Toshiaki Saeki Kenji Kawada Tadahiko Igarashi Noriko Usubuchi Ryuzo Ueda Yasutsuna Sasaki Hironobu Minami | 2005 | Cancer Chemotherapy and Pharmacology2005，，2： | 1 |
| 9 | Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer显示文摘 | Ken-ichi Fujita Yuichi Ando Fumio Nagashima Wataru Yamamoto Hisashi Eodo Kazuhiro Araki Keiji Kodama Toshimichi Miya Masaru Narabayashi Yasutsuna Sasaki | 2007 | Cancer Chemotherapy and Pharmacology2007，，4： | 1 |
| 10 | Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial显示文摘 | Yasuhide Yamada Daisuke Takahari Hiroshi Matsumoto Hideo Baba Masato Nakamura Kazuhiro Yoshida Motoki Yoshida Shigeyoshi Iwamoto Ken Shimada Yoshito Komatsu Yasutsuna Sasaki Taroh Satoh Keiichi Takahashi Hideyuki Mishima Kei Muro Masahiko Watanabe Yuh Sak | 2013 | Lancet Oncology2013，，13： | 1 |
| 11 | Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5′-deoxy-5-fluorouridine (5′-DFUR)显示文摘 | Hiromichi Ebi Yasushi Sigeoka Toshiaki Saeki Kenji Kawada Tadahiko Igarashi Noriko Usubuchi Ryuzo Ueda Yasutsuna Sasaki Hironobu Minami | 2005 | Cancer Chemotherapy and Pharmacology2005，，2： | 1 |
| 12 | Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11显示文摘 | Yasutsuna S Yasushi Y Kenichi S | 1995 | Jpn J Cancer Res1995，86，： | 1 |
| 13 | A phase I study of farletuzumab, a humanized anti-folate receptor a monoclonal antibody, in patients with solid tumors 显示文摘 | Yasutsuna S Keisuke M Keishi Y | 2015 | Nvest New Drugs2015，33，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员